ADC Therapeutics (ADCT) EPS (Weighted Average and Diluted) (2023 - 2026)
ADC Therapeutics' (ADCT) quarterly EPS (Weighted Average and Diluted) came in at -$0.21 in Q1 2026, up 41.67% year-on-year from -$0.15 in Q1 2025, and up 30.0% quarter-over-quarter from -$0.3 in Q3 2025.
ADC Therapeutics (ADCT) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
ADC Therapeutics has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.21 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | -0.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.21 |
| Sep 30, 2025 | -0.30 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | -0.36 |
| Sep 30, 2024 | -0.42 |
| Jun 30, 2024 | -0.38 |
| Mar 31, 2024 | -0.56 |
| Sep 30, 2023 | -0.57 |
| Jun 30, 2023 | -0.60 |